Paxman launches cryocompression system to target chemotherapy neuropathy

Paxman has launched the Paxman Neuropathy System, a cryocompression device aimed at reducing the risk and severity of chemotherapy-induced peripheral neuropathy. The rollout begins in six European markets as new clinical data and ongoing studies add to evidence for the approach.

Why it matters: - Chemotherapy-induced peripheral neuropathy, or CIPN, can cause numbness, pain, tingling and loss of sensation in the hands and feet. - CIPN can also force cancer treatment delays, dose reductions or discontinuation. - Paxman is trying to address one of oncology’s biggest unmet needs beyond scalp cooling.

What happened: - Paxman announced the commercial launch of the Paxman Neuropathy System, a cryocompression device designed to help reduce the risk and severity of CIPN. - The launch marks Paxman’s first major expansion beyond scalp cooling, which the company uses to manage chemotherapy-induced hair loss. - The system is launching in the United Kingdom, France, Germany, the Netherlands, Spain and Italy after recent regulatory approvals.

The details: - Paxman has been a global leader in scalp cooling for more than 25 years. - The company’s position was strengthened by its acquisition of Dignitana in 2025. - The new product extends Paxman’s portfolio into other treatment-related side effects with long-term impact on patients. - A multicenter prospective phase I/II study published in JCO Oncology Advances evaluated the system in patients receiving taxane-based chemotherapy. - The study found the device was safe, well tolerated and linked to low rates of CIPN. - Among 146 evaluable patients, none developed severe neuropathy. - Patient-reported clinically significant sensory symptoms remained low throughout follow-up. - A separate review in Therapeutic Advances in Medical Oncology examined the causes, impact and potential prevention strategies for CIPN. - That review highlighted cryotherapy and cryocompression as among the most promising emerging interventions.

Between the lines: - Paxman is broadening its strategy from hair-loss management to a wider oncology supportive-care platform. - The move puts the company in a growing race to offer practical ways to keep patients on prescribed chemotherapy. - The new data do not establish a standard-of-care prevention option, but they add momentum behind cryocompression as a preventive approach.

What's next: - Pilot programs are already running in the U.K., with expansion to additional European centers planned over the next few months. - Research is continuing in the U.S. through the randomized SWOG S2205 ICE COMPRESS study. - Dana-Farber Cancer Institute is also running an additional clinical trial to evaluate the Paxman Neuropathy System. - Richard Paxman OBE, Paxman’s CEO, said the launch marks a new chapter for the company and reflects its commitment to innovative cancer-support technologies.